Seok-Joong Yun

List of Publications by Year
in descending order

139 papers	2,207 citations	331538 21 h-index	302012 39 g-index
139 all docs	139 docs citations	139 times ranked	3313 citing authors

#	Article	IF	Citations
1	Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Molecular Cancer, 2010, 9, 3.	7.9	309
2	Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. International Journal of Oncology, 2012, 41, 1871-1878.	1.4	134
3	Impact of Obesity in Patients With Urolithiasis and its Prognostic Usefulness in Stone Recurrence. Journal of Urology, 2008, 179, 570-574.	0.2	84
4	Role of the Epithelial-Mesenchymal Transition in Bladder Cancer: From Prognosis to Therapeutic Target. Korean Journal of Urology, 2013, 54, 645.	1.2	74
5	A Four-Gene Signature Predicts Disease Progression in Muscle Invasive Bladder Cancer. Molecular Medicine, 2011, 17, 478-485.	1.9	60
6	Cell-Free microRNA-214 From Urine as a Biomarker for Non-Muscle-Invasive Bladder Cancer. Korean Journal of Urology, 2013, 54, 791.	1.2	59
7	Anti-Proliferative and Pro-Apoptotic Effects of Licochalcone A through ROS-Mediated Cell Cycle Arrest and Apoptosis in Human Bladder Cancer Cells. International Journal of Molecular Sciences, 2019, 20, 3820.	1.8	46
8	TOX-expressing terminally exhausted tumor-infiltrating CD8+ T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer. Cancer Letters, 2021, 499, 137-147.	3.2	42
9	The p21-activated kinase 4-Slug transcription factor axis promotes epithelialâˆ'mesenchymal transition and worsens prognosis in prostate cancer. Oncogene, 2018, 37, 5147-5159.	2.6	41
10	Urinary MicroRNAs of Prostate Cancer: Virus-Encoded hsv1-miRH18 and hsv2-miR-H9-5p Could Be Valuable Diagnostic Markers. International Neurourology Journal, 2015, 19, 74-84.	0.5	40
11	Role of Exosomal miRNA in Bladder Cancer: A Promising Liquid Biopsy Biomarker. International Journal of Molecular Sciences, 2021, 22, 1713.	1.8	36
12	Isorhamnetin Induces Cell Cycle Arrest and Apoptosis Via Reactive Oxygen Species-Mediated AMP-Activated Protein Kinase Signaling Pathway Activation in Human Bladder Cancer Cells. Cancers, 2019, 11, 1494.	1.7	33
13	Forkhead box O-class 1 and Forkhead box G1 as Prognostic Markers for Bladder Cancer. Journal of Korean Medical Science, 2009, 24, 468.	1.1	32
14	Expectant Management of Ureter Stones: Outcome and Clinical Factors of Spontaneous Passage in a Single Institution's Experience. Korean Journal of Urology, 2011, 52, 847.	1.2	30
15	HSP70-1 is required for interleukin-5-induced angiogenic responses through eNOS pathway. Scientific Reports, 2017, 7, 44687.	1.6	30
16	Urinary cellâ€free microRNA biomarker could discriminate bladder cancer from benign hematuria. International Journal of Cancer, 2019, 144, 380-388.	2.3	30
17	Novel Combination Markers for Predicting Survival in Patients with Muscle Invasive Bladder Cancer: USP18 and DGCR2. Journal of Korean Medical Science, 2014, 29, 351.	1.1	29
18	Expression levels of FGFR3 as a prognostic marker for the progression of primary pT1 bladder cancer and its association with mutation status. Oncology Letters, 2017, 14, 3817-3824.	0.8	29

#	Article	IF	Citations
19	Prostate Size Correlates with Fasting Blood Glucose in Non-Diabetic Benign Prostatic Hyperplasia Patients with Normal Testosterone Levels. Journal of Korean Medical Science, 2011, 26, 1214.	1.1	28
20	Glucose-derived acetate and ACSS2 as key players in cisplatin resistance in bladder cancer. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2019, 1864, 413-421.	1.2	26
21	The age-adjusted Charlson comorbidity index as a predictor of overall survival of surgically treated non-metastatic clear cell renal cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2020, 146, 187-196.	1.2	24
22	Influence of Obesity on Short-term Surgical Outcome of the Transobturator Tape Procedure in Patients with Stress Urinary Incontinence. International Neurourology Journal, 2010, 14, 13.	0.5	23
23	Hypertriglyceridemia Is Associated With Increased Risk for Stone Recurrence in Patients With Urolithiasis. Urology, 2014, 84, 766-771.	0.5	21
24	Collagen typeÂVIâ€Î±1 and 2 repress the proliferation, migration and invasion of bladder cancer cells. International Journal of Oncology, 2021, 59, .	1.4	21
25	mRNA Expression of S100A8 as a Prognostic Marker for Progression of Non-Muscle-Invasive Bladder Cancer. Korean Journal of Urology, 2010, 51, 15.	1.2	20
26	Impact of Young Age at Diagnosis on Survival in Patients with Surgically Treated Renal Cell Carcinoma: a Multicenter Study. Journal of Korean Medical Science, 2016, 31, 1976.	1.1	20
27	Protective effect of diphlorethohydroxycarmalol against oxidative stress-induced DNA damage and apoptosis in retinal pigment epithelial cells. Cutaneous and Ocular Toxicology, 2019, 38, 298-308.	0.5	20
28	Identification of differentially expressed miRNAs and miRNA-targeted genes in bladder cancer. Oncotarget, 2018, 9, 27656-27666.	0.8	20
29	How do we manage high-grade T1 bladder cancer? Conservative or aggressive therapy?. Investigative and Clinical Urology, 2016, 57, S44.	1.0	19
30	*CDC6* mRNA Expression Is Associated with the Aggressiveness of Prostate Cancer. Journal of Korean Medical Science, 2018, 33, e303.	1.1	19
31	A Low Geriatric Nutritional Risk Index is Associated with Aggressive Pathologic Characteristics and Poor Survival after Nephrectomy in Clear Renal Cell Carcinoma: A Multicenter Retrospective Study. Nutrition and Cancer, 2020, 72, 88-97.	0.9	19
32	Prognostic Impact of Nutritional Status Assessed by the Controlling Nutritional Status (CONUT) Score in Patients with Surgically Treated Renal Cell Carcinoma. Nutrition and Cancer, 2018, 70, 886-894.	0.9	18
33	Prognostic Significance of CREB-Binding Protein and CD81 Expression in Primary High Grade Non-Muscle Invasive Bladder Cancer: Identification of Novel Biomarkers for Bladder Cancer Using Antibody Microarray. PLoS ONE, 2015, 10, e0125405.	1.1	18
34	DNA Methylation of *GSTP1* in Human Prostate Tissues: Pyrosequencing Analysis. Korean Journal of Urology, 2012, 53, 200.	1.2	17
35	Elevated Insulin and Insulin Resistance Are Associated with the Advanced Pathological Stage of Prostate Cancer in Korean Population. Journal of Korean Medical Science, 2012, 27, 1079.	1.1	17
36	Induction of Apoptosis by *Citrus unshiu* Peel in Human Breast Cancer MCF-7 Cells: Involvement of ROS-Dependent Activation of AMPK. Biological and Pharmaceutical Bulletin, 2018, 41, 713-721.	0.6	17

#	Article	IF	Citations
37	Methylation Signature for Prediction of Progression Free Survival in Surgically Treated Clear Cell Renal Cell Carcinoma. Journal of Korean Medical Science, 2019, 34, e144.	1.1	17
38	Preoperative Underweight Patients with Upper Tract Urothelial Carcinoma Survive Less after Radical Nephroureterectomy. Journal of Korean Medical Science, 2015, 30, 1483.	1.1	16
39	Sodium Restriction as Initial Conservative Treatment for Urinary Stone Disease. Journal of Urology, 2010, 184, 1372-1376.	0.2	15
40	<i>GSTM1</i> Tissue Genotype as a Recurrence Predictor in Non-muscle Invasive Bladder Cancer. Journal of Korean Medical Science, 2011, 26, 231.	1.1	15
41	Comparison of mRNA, Protein, and Urinary Nucleic Acid Levels of S100A8 and S100A9 between Prostate Cancer and BPH. Annals of Surgical Oncology, 2015, 22, 2439-2445.	0.7	15
42	DUSP1 induces paclitaxel resistance through the regulation of p-glycoprotein expression in human ovarian cancer cells. Biochemical and Biophysical Research Communications, 2016, 478, 403-409.	1.0	15
43	Induction of Apoptosis by Coptisine in Hep3B Hepatocellular Carcinoma Cells through Activation of the ROS-Mediated JNK Signaling Pathway. International Journal of Molecular Sciences, 2020, 21, 5502.	1.8	15
44	Betulinic Acid Restricts Human Bladder Cancer Cell Proliferation In Vitro by Inducing Caspase-Dependent Cell Death and Cell Cycle Arrest, and Decreasing Metastatic Potential. Molecules, 2021, 26, 1381.	1.7	15
45	Granular Cell Tumor of the Urinary Bladder. Korean Journal of Urology, 2010, 51, 291.	1.2	14
46	The c-MET Network as Novel Prognostic Marker for Predicting Bladder Cancer Patients with an Increased Risk of Developing Aggressive Disease. PLoS ONE, 2015, 10, e0134552.	1.1	14
47	Kinesin Family Member 11 mRNA Expression Predicts Prostate Cancer Aggressiveness. Clinical Genitourinary Cancer, 2017, 15, 450-454.	0.9	14
48	Urinary microRNA-1913 to microRNA-3659 expression ratio as a non-invasive diagnostic biomarker for prostate cancer. Investigative and Clinical Urology, 2021, 62, 340.	1.0	14
49	Investigational cell cycle inhibitors in clinical trials for bladder cancer. Expert Opinion on Investigational Drugs, 2013, 22, 369-377.	1.9	13
50	Role of 1,25-Dihydroxy Vitamin D₃ and Parathyroid Hormone in Urinary Calcium Excretion in Calcium Stone Formers. Yonsei Medical Journal, 2014, 55, 1326.	0.9	13
51	Effect of Renal Insufficiency on Stone Recurrence in Patients with Urolithiasis. Journal of Korean Medical Science, 2014, 29, 1132.	1.1	13
52	Assess the expression of ubiquitin specific protease USP2a for bladder cancer diagnosis. BMC Urology, 2015, 15, 80.	0.6	12
53	Urinary Cell-Free DNA IQGAP3/BMP4 Ratio as a Prognostic Marker for Non–Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2019, 17, e704-e711.	0.9	12
54	A prognostic immune predictor, HLA-DRA, plays diverse roles in non-muscle invasive and muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 237.e21-237.e29.	0.8	12

#	Article	IF	Citations
55	Increased Expression of Herpes Virus-Encoded hsv1-miR-H18 and hsv2-miR-H9-5p in Cancer-Containing Prostate Tissue Compared to That in Benign Prostate Hyperplasia Tissue. International Neurourology Journal, 2016, 20, 122-130.	0.5	12
56	<i>GSTT1</i> as a Prognosticator for Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer. Disease Markers, 2010, 29, 81-87.	0.6	11
57	Phosphaturia as a Promising Predictor of Recurrent Stone Formation in Patients with Urolithiasis. Korean Journal of Urology, 2010, 51, 54.	1.2	11
58	Comparison of Metabolic Risk Factors in Urolithiasis Patients according to Family History. Korean Journal of Urology, 2010, 51, 50.	1.2	11
59	Pre-Clinical Efficacy and Safety Evaluation of Human Amniotic Fluid-Derived Stem Cell Injection in a Mouse Model of Urinary Incontinence. Yonsei Medical Journal, 2015, 56, 648.	0.9	11
60	National practice patterns and direct medical costs for prostate cancer in Korea across a 10‰year period: a nationwide population-based study using a national health insurance database. BMC Health Services Research, 2019, 19, 408.	0.9	11
61	Diagnostic value of combined IQGAP3/BMP4 and IQGAP3/FAM107A expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 86-96.	0.8	11
62	Tumor heterogeneity in muscle-invasive bladder cancer. Translational Andrology and Urology, 2020, 9, 2866-2880.	0.6	11
63	Docetaxel-Induced Fatal Interstitial Pneumonitis in a Patient with Castration-Resistant Prostate Cancer. Korean Journal of Urology, 2012, 53, 371.	1.2	10
64	Usefulness of a Combined Approach of T1-Weighted, T2-Weighted, Dynamic Contrast-Enhanced, and Diffusion-Weighted Imaging in Prostate Cancer. Korean Journal of Urology, 2012, 53, 830.	1.2	10
65	Comparative analysis of benign prostatic hyperplasia management by urologists and nonurologists: A Korean nationwide health insurance database study. Korean Journal of Urology, 2015, 56, 233.	1.2	10
66	Evaluation of the Immune Responses to and Cross-Protective Efficacy of Eurasian H7 Avian Influenza Viruses. Journal of Virology, 2017, 91, .	1.5	10
67	Impact of the ASA Physical Status Score on Adjuvant Chemotherapy Eligibility and Survival of Upper Tract Urothelial Carcinoma Patients: a Multicenter Study. Journal of Korean Medical Science, 2017, 32, 335.	1.1	10
68	The Prognosis and Oncological Predictor of Urachal Carcinoma of the Bladder: A Large Scale Multicenter Cohort Study Analyzed 203 Patients With Long Term Follow-Up. Frontiers in Oncology, 2021, 11, 683190.	1.3	10
69	Medical Travel among Non-Seoul Residents to Seek Prostate Cancer Treatment in Medical Facilities of Seoul. Cancer Research and Treatment, 2019, 51, 53-64.	1.3	10
70	A Large Stone in the Dilated Left Seminal Vesicle: Laparoscopic Removal and Partial Seminal Vesiculectomy. Korean Journal of Urology, 2008, 49, 656.	0.2	9
71	The predictive value of GSTT1 polymorphisms in predicting the early response to induction BCG therapy in patients with non‑muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 458-465.	0.8	9
72	A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer. Oncology Letters, 2020, 19, 476-486.	0.8	9

#	Article	IF	Citations
73	Effects of Previous or Synchronous Non-Muscle Invasive Bladder Cancer on Clinical Results after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multi-Institutional Study. Urology Journal, 2015, 12, 2233-9.	0.3	9
74	Changes in Urinary Lithogenic Features Over Time in Patients With Urolithiasis. Urology, 2009, 74, 51-55.	0.5	8
75	FAM70Bas a Novel Prognostic Marker for Cancer Progression and Cancer-Specific Death in Muscle-Invasive Bladder Cancer. Korean Journal of Urology, 2012, 53, 598.	1.2	8
76	Decreased *DBC1* Expression Is Associated With Poor Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer. Korean Journal of Urology, 2013, 54, 631.	1.2	8
77	Lower Levels of Human MOB3B Are Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics. Journal of Korean Medical Science, 2015, 30, 937.	1.1	8
78	Clinical Implications and Prognostic Values of *Prostate Cancer Susceptibility Candidate* Methylation in Primary Nonmuscle Invasive Bladder Cancer. Disease Markers, 2015, 2015, 1-6.	0.6	8
79	Molecular Progression Risk Score for Prediction of Muscle Invasion in Primary T1 High-Grade Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, 274-280.	0.9	8
80	Citrus unshiu peel suppress the metastatic potential of murine melanoma B16F10 cells in vitro and in vivo. Phytotherapy Research, 2019, 33, 3228-3241.	2.8	8
81	Twenty-four-hour urine osmolality as a representative index of adequate hydration and a predictor of recurrence in patients with urolithiasis. International Urology and Nephrology, 2019, 51, 1129-1135.	0.6	8
82	Alpha-Methylacyl-Coenzyme A Racemase-Expressing Urachal Adenocarcinoma of the Abdominal Wall. Korean Journal of Urology, 2010, 51, 498.	1.2	7
83	Urinary Nucleic Acid *TSPAN13*-to-*S100A9* Ratio as a Diagnostic Marker in Prostate Cancer. Journal of Korean Medical Science, 2015, 30, 1784.	1.1	7
84	Metabolic Characteristics and Risks Associated with Stone Recurrence in Korean Young Adult Stone Patients. Journal of Endourology, 2017, 31, 806-811.	1.1	7
85	Chronological Trends in Clinical and Urinary Metabolic Features over 20 Years in Korean Urolithiasis Patients. Journal of Korean Medical Science, 2017, 32, 1496.	1.1	7
86	A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone. Investigative and Clinical Urology, 2020, 61, 411.	1.0	7
87	Prognostic Value of BUB1 for Predicting Non-Muscle-Invasive Bladder Cancer Progression. International Journal of Molecular Sciences, 2021, 22, 12756.	1.8	7
88	Pyrosequencing Analysis ofAPCMethylation Level in Human Prostate Tissues: A Molecular Marker for Prostate Cancer. Korean Journal of Urology, 2013, 54, 194.	1.2	6
89	Antiangiogenic Therapy with Human Apolipoprotein(a) Kringle V and Paclitaxel in a Human Ovarian Cancer Mouse Model. Translational Oncology, 2014, 7, 368-376.	1.7	6
90	Long-term validation of a molecular progression-associated gene classifier for prediction of muscle invasion in primary non-muscle-invasive bladder cancer. Oncology Letters, 2017, 14, 2468-2474.	0.8	6

#	Article	IF	Citations
91	For Physicians Managing Voiding Dysfunction, Improving the Detection Rate of Early Prostate Cancer and Discrimination From Benign Prostatic Hyperplasia, in a Molecular Biomarker Aspects. International Neurourology Journal, 2019, 23, 5-12.	0.5	6
92	ZNF492 and GPR149 methylation patterns as prognostic markers for clear cell renal cell carcinoma: Array‐based DNA methylation profiling. Oncology Reports, 2019, 42, 453-460.	1.2	6
93	The immunostimulatory effect of indole-6-carboxaldehyde isolated from *Sargassum thunbergii* **(Mertens) Kuntze** in RAW 264.7 macrophages. Animal Cells and Systems, 2020, 24, 233-241.	0.8	6
94	Trends in End-of-Life Resource Utilization and Costs among Prostate Cancer Patients from 2006 to 2015: A Nationwide Population-Based Study. World Journal of Men?s Health, 2021, 39, 158.	1.7	6
95	A Molecular Signature Determines the Prognostic and Therapeutic Subtype of Non-Muscle-Invasive Bladder Cancer Responsive to Intravesical Bacillus Calmette-GuÃ©rin Therapy. International Journal of Molecular Sciences, 2021, 22, 1450.	1.8	6
96	The prognostic value of the pretreatment serum albumin to globulin ratio for predicting adverse pathology in patients undergoing radical prostatectomy for prostate cancer. Investigative and Clinical Urology, 2021, 62, 545.	1.0	6
97	Characteristics of Renal Cell Carcinoma Harboring TPM3-ALK Fusion. Yonsei Medical Journal, 2020, 61, 262.	0.9	6
98	Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting. Investigative and Clinical Urology, 2020, 61, 19.	1.0	6
99	Comparison of the Effect of Naftopidil 75 mg and Tamsulosin 0.2 mg on the Bladder Storage Symptom With Benign Prostatic Hyperplasia: Prospective, Multi-institutional Study. Urology, 2018, 111, 145-150.	0.5	5
100	Acute and Serious Myositis with Abscess in Thigh Muscle after Transobturator Tape Implantation. International Neurourology Journal, 2010, 14, 182.	0.5	5
101	Expression of hsv1-miR-H18 and hsv2-miR-H9 as a field defect marker for detecting prostate cancer. Prostate International, 2022, 10, 1-6.	1.2	5
102	Utility of Smo as a Prognostic Marker for Human Bladder Tumors. Korean Journal of Urology, 2007, 48, 997.	0.2	4
103	The Comparison between Transperineal and Transrectal Ultrasound-Guided Prostate Needle Biopsy. Korean Journal of Urology, 2009, 50, 119.	1.2	4
104	Distinct Metabolic Characteristics and Risk of Stone Recurrence in Patients With Multiple Stones at the First-time Presentation. Urology, 2014, 84, 274-278.	0.5	4
105	Necrotizing fasciitis associated with sorafenib treatment. IDCases, 2019, 18, e00611.	0.4	4
106	Prominence of urinary biomarkers for bladder cancer in the COVID-19 era: From the commercially available to new prospective candidates. Investigative and Clinical Urology, 2021, 62, 500.	1.0	4
107	A high basal metabolic rate is an independent predictor of stone recurrence in obese patients. Investigative and Clinical Urology, 2021, 62, 195.	1.0	4
108	Generation of 1E8 Single Chain Fv-Fc Construct Against Human CD59. Immune Network, 2012, 12, 33.	1.6	3

#	Article	IF	Citations
109	Impact of Transobturator Tape Treatment on Overactive Bladder Symptoms, Particularly Nocturia, in Patients With Mixed Urinary Incontinence. Korean Journal of Urology, 2014, 55, 520.	1.2	3
110	Virus encoded circulatory miRNAs for early detection of prostate cancer. BMC Urology, 2015, 15, 116.	0.6	3
111	Bilateral Obstructive Uropathy Caused by Congenital Bladder Diverticulum Presenting as Hypertensive Retinopathy. Journal of Korean Medical Science, 2018, 33, e54.	1.1	3
112	Evaluation of the In Vitro and In Vivo Antitumor Efficacy of Peanut Sprout Extracts Cultivated with Fermented Sawdust Medium Against Bladder Cancer. Applied Sciences (Switzerland), 2020, 10, 8758.	1.3	3
113	Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone. Investigative and Clinical Urology, 2022, 63, 238.	1.0	3
114	Induction of apoptotic cell death in human bladder cancer cells by ethanol extract of *Zanthoxylum schinifolium* leaf, through ROS-dependent inactivation of the PI3K/Akt signaling pathway. Nutrition Research and Practice, 2022, 16, 330.	0.7	3
115	Effects of Metabolic Syndrome on Chronic Kidney Disease. Korean Journal of Urology, 2009, 50, 261.	1.2	2
116	Change in Prostate Specific Antigen Concentration in Men with Prostate Specific Antigen Less than 2.5 ng/ml Taking Low Dose Finasteride or Dutasteride for Male Androgenetic Alopecia. Journal of Urology, 2017, 198, 1340-1345.	0.2	2
117	Expression of phosphorylated p21-activated kinase 4 is associated with aggressive histologic characteristics and poor prognosis in patients with surgically treated renal cell carcinoma. Investigative and Clinical Urology, 2021, 62, 399.	1.0	2
118	Nutritional status assessed by the Controlling Nutritional Status (CONUT) score as a predictor of recurrence of urolithiasis. Investigative and Clinical Urology, 2021, 62, 553.	1.0	2
119	The Relationship between RUNX3 Inactivation and Its Pathological Features in Renal Cell Carcinoma. Korean Journal of Urology, 2009, 50, 432.	1.2	2
120	Trends in clinical, operative, and pathologic characteristics of surgically treated renal mass in a Korean center: A surgical series from 1988 through 2015. Investigative and Clinical Urology, 2019, 60, 184.	1.0	2
121	Expression of RPL9 predicts the recurrence of non-muscle invasive bladder cancer with BCG therapy. Urologic Oncology: Seminars and Original Investigations, 2022, , .	0.8	2
122	Tubal Buccal Mucosa Graft without Anastomosis of the Proximal Urethra for Long Segment Posterior Urethral Defect Repair. Korean Journal of Urology, 2012, 53, 737.	1.2	1
123	Can lymphovascular invasion replace the prognostic value of lymph node involvement in patients with upper tract urothelial carcinoma after radical nephroureterectomy?. Canadian Urological Association Journal, 2016, 10, 229.	0.3	1
124	Effect of pre-operative internal obturator muscle mass index in MRI on biochemical recurrence of prostate cancer patients after radical prostatectomy: a multi-center study. BMC Urology, 2021, 21, 85.	0.6	1
125	The Role of MicroRNAs in Oncogenesis and Progression of Prostate Cancer. The Korean Journal of Urological Oncology, 2018, 16, 1-6.	0.1	1
126	Generation of Whole-Genome Sequencing Data for Comparing Primary and Castration-Resistant Prostate Cancer. Genomics and Informatics, 2018, 16, 71-74.	0.4	1

#	Article	IF	Citations
127	Locally recurrent penile apocrine carcinoma initially diagnosed as metastatic adenocarcinoma of colon. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2013, 25, 777-80.	0.7	1
128	The therapeutic and prognostic implications of molecular biomarkers in urothelial carcinoma. Translational Cancer Research, 2020, 9, 6609-6623.	0.4	1
129	A Primary Large Cell Neuroendocrine Carcinoma of the Urinary Bladder in a 19-year-old Man. Korean Journal of Urology, 2008, 49, 647.	0.2	0
130	Comparison of Clinico-Metabolic Characteristics between Calcium Oxalate and Uric Acid Stone Formers. Korean Journal of Urology, 2009, 50, 897.	1.2	0
131	Diagnostic Role of Prostate Resection in the Elderly Patients Who Experience Significant Co-Morbidity with a High Clinical Suspicion of Prostate Cancer. Journal of Korean Medical Science, 2013, 28, 1796.	1.1	0
132	Microbiome of Genitourinary Tumors: Especially in Prostate Cancer and Kidney Cancer. The Korean Journal of Urological Oncology, 2021, 19, 136-147.	0.1	0
133	The Expression and Clinical Implications of Forkhead Trasnscription Factor FKHR (FOXO1) in Human Bladder Cancer. Korean Journal of Urology, 2007, 48, 396.	0.2	0
134	Anticancer Effect ofMagnolia officinalis'Extract on N-butyl-N-(4-hydroxybutyl) Nitrosamine Induced Bladder Cancer in Mice. Korean Journal of Urology, 2008, 49, 682.	0.2	0
135	Changes in Voiding Patterns after Transobturator Tape Operation in Female Patients with Stress Urinary Incontinence. Korean Journal of Urology, 2008, 49, 609.	0.2	0
136	Clinical Significance of the Expression of Gli2 and Gli3 in Bladder Cancer. Korean Journal of Urology, 2008, 49, 696.	0.2	0
137	The Trend of Uro-Oncologist About Blood Test and Imaging Studies for the Diagnosis of Biochemical Recurrence in Korea. The Korean Journal of Urological Oncology, 2017, 15, 131-136.	0.1	0
138	Precision Medicine in Castration-Resistant Prostate Cancer. The Korean Journal of Urological Oncology, 2018, 16, 97-102.	0.1	0
139	Predictive Molecular and Protein Markers for the Recurrence of Nonmuscle Invasive Bladder Cancer. The Korean Journal of Urological Oncology, 2019, 17, 81-87.	0.1	0